Pharmacogenetics of cutaneous adverse drug reactions

Journal of Dermatology

Volumn 38, Issue 3, 2011, Pages 246-254

  Aihara, Michiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

adverse drug reaction; drug induced hypersensitivity syndrome; pharmacogenetics; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ALLOPURINOL; CARBAMAZEPINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA B75 ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; LAMOTRIGINE; NEVIRAPINE; OXCARBAZEPINE; PHENYTOIN; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; ASIAN; CAUCASIAN; CHINESE; DRESS SYNDROME; DRUG HYPERSENSITIVITY; DRUG SAFETY; ERYTHEMA MULTIFORME; ERYTHRODERMA; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GOUT; HOMOZYGOTE; HUMAN; HUMAN HERPESVIRUS 6; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; JAPANESE; MACULOPAPULAR RASH; PHARMACOGENOMICS; RISK FACTOR; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; VIRUS REACTIVATION;

ALLOPURINOL; ANTI-RETROVIRAL AGENTS; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; DRUG ERUPTIONS; ENZYME INHIBITORS; EPIDERMAL NECROLYSIS, TOXIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS; STEVENS-JOHNSON SYNDROME;

EID: 79952010199     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01196.x     Document Type: Article

References (46)

1. Bastuji-Garins S, Rzany B, Stern RS, et al. Clinical Classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-96. (Pubitemid 23029676)
2. Roujeau JC,. Stevens-Johnson Syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-729.
3. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49: 769-773. (Pubitemid 26280728)
4. Schneck J, Stat D, Fagot J-P, et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40. (Pubitemid 350298143)
5. Shiohara T, Inaoka M, Kano Y,. Drug-induced hyperdensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesvirus and antiviraland antidrug immune responses. Allerg Int 2006; 55: 1-8.
6. Eshki M, Allanore L, Musette P, et al. Twenty-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable organ failure. Arch Dermatol 2009; 145: 67-72.
7. Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007; 157: 934-940. (Pubitemid 47583515)
8. Kano Y, Hirahara K, Sakuma K, et al. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006; 155: 301-306. (Pubitemid 44050562)
9. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14: 1343-1350.
10. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
11. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-1018. (Pubitemid 46763406)
12. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49: 2087-2091.
13. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268. (Pubitemid 44137953)
14. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801allele as a genetic marker for severe cutaneous adverse drug reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-4139.
15. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
16. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
17. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579-582.
18. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51: 926-930.
19. Lonjou C, Thomas L, Borot N, et al.; RegiSCAR Group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
20. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617-1622.
21. Ikeda H, Takahashi Y, Yamazaki E, et al. HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010; 51: 297-300.
22. Kaniwa N, Saito Y, Aihara M, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010; 51: 2461-2465.
23. Kashiwagi M, Aihara M, Takahashi Y, Muramatsu M, Ikezawa Z,. HLA genotypes in carbamazepine induced severe cutaneous adverse drug response in Japanese patients. J Dermatol 2008; 35: 683-685.
24. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S,. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008; 14: 550-555. (Pubitemid 351472356)
25. Middleton D, Menchaca L, Rood H, Komerofsky R,. New allele frequency database:. Tissue Antigens 2003; 61: 403-407.
26. Sierra NM, Garcia B, Marco J, et al. Cross hypersensitivity syndrome between phenitoin and carbamazepine. Pharm World Sci 2005; 24: 170-174. (Pubitemid 41159965)
27. Romano A, Pettinato R, Andriolo M, et al. Hypersensitivity to aromatic Abacaviraniticonvulsants: in vivo and in vitro cross reactivity studies. Curr Pharm Des 2006; 12: 3372-3381.
28. Hung SI, Chung WH, Liu ZS, et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010; 11: 349-356.
29. Alfirevic A, Jorgensen AL, Wiliamson PR, Chadwick DW, Park BK, Pirmohamed M,. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 97: 813-818. (Pubitemid 44446732)
30. Kano Y, Hirahara K, Asano Y, et al. HLA-B allele associations with certain drug are not confirmed in Japanese patients with severe cutaneous drug reactions. Acta Derm Venereol 2008; 88: 616-618.
31. Tokunaga k, Ishikawa Y, Ogawa A, et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 1997; 46: 199-205. (Pubitemid 27292360)
32. Tassaneevakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704-709.
33. Dainichi T, Uchi H, Moroi Y, Furue M,. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatol 2007; 215: 86-88. (Pubitemid 46976024)
34. Phillips EJ, Mallal SA,. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2010; 11: 973-987.
35. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-1614. (Pubitemid 33063588)
36. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reaction to abacavir. Lancet 2002; 359: 1121-1122. (Pubitemid 34270738)
37. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732. (Pubitemid 34215071)
38. Gatanaga H, Honda H, Oka S,. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008; 9: 207-214. (Pubitemid 351566944)
39. Hughes AR, Mosreller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 207-214.
40. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46: 1111-1118. (Pubitemid 351589880)
41. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579. (Pubitemid 351214284)
42. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009; 19: 136-145.
43. Littera R, Carcassi C, Masala A, et al. HLA-dependant hypersensitivity to nevirapine in Sardinian patients. AIDS 2006; 20: 1621-1626. (Pubitemid 44162404)
44. Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21: 264-265. (Pubitemid 46036947)
45. Tanaka H, Akaza T, Juji T,. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 1996: 139-144.
46. Yang G, Deng YJ, Qin H, et al. HLA-B*15 subtypes distribution in Han population in Beijing, China, as compared with those of other populations. Int J Immunogenet 2010; 37: 205-212.